Logo for Idogen

Idogen Investor Relations Material

Latest events

Logo for Idogen

Q1 2023

9 May, 2023
Logo for Idogen

Q4 2022

24 Feb, 2023
Access the full event backlog
Slides, Transcripts, and Reports from over 8,000 public companies
Idogen AB (publ) is a biotechnology company, which develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs and the body's own cells or tissues. The company's advanced product candidate IDO 8 is designed for patients with severe haemophilia A who have developed neutralizing antibodies against critical treatment with coagulation factor VIII. It also develops IDO T, a tolerogenic cell therapy to prevent organ transplant rejection primarily kidney transplantation; and IDO AID for the treatment of autoimmune diseases.